Promotional material

Vaccine update: issue 348, August 2024, back-to-school special

Updated 22 August 2024

Applies to England

Back-to-school season: make sure that children are protected for the new school year

This issue lands as the summer break ends and our focus is on helping children get a healthy start to the new school year by ensuring they are up to date with all their routine vaccinations.

This is particularly important as high measles activity continues with 2,278 laboratory confirmed cases in England since 1 January this year and 153 confirmed cases in the last 4 weeks (up to 5 August). 62% of these cases are children aged 10 years of age and under ^{[footnote 1]}. Cases have been seen in all English regions with initial large outbreaks occurring in the West Midlands, but most cases (45%) are now arising in London.

This high measles activity is also being seen across Europe and around the world. During May 2024 over 600 cases were reported by 18 EU/EEA member states and over 6,700 cases were reported over the preceding 12 months, from 1 June 2023 to 31 May 2024 ^{[footnote 2]}. There is therefore the additional risk of importation of infection as families return from overseas travel in time for the start of the autumn term and this could seed outbreaks anywhere in the UK.

Last year in our August 2023 vaccine update we highlighted modelling work undertaken by the UK Health Security Agency (UKHSA) which served as a warning of the potential size measles outbreaks could reach in the UK, due to high levels of susceptibility in specific populations, including teenagers, young people and under-vaccinated communities ^{[footnote 3]}.

Rebecca Cordery, Consultant Epidemiologist Measles, notes:

Unfortunately, measles activity did increase in England in the autumn 2023 and UKHSA raised its incident response level to a National Standard Incident in January 2024.

Multi-agency partners across the health system have since worked tirelessly to support individuals and communities experiencing outbreaks. Measles infection can result in serious complications and long-term disability, particularly in those who are immunosuppressed, infants and pregnant women. As most cases seek medical attention and between 20% and 40% of cases require hospitalisation, current high levels of infection put significant pressure on hospitals and GP surgeries in outbreak areas. This is not just by providing clinical care to patients but also supporting contact tracing and identifying exposed vulnerable individuals who may require urgent post exposure prophylaxis.

The immense efforts made by local and regional partners to improve vaccine uptake in susceptible communities over the last year have been supplemented by a national MMR call/re-call campaign launched by NHS England in November 2023 ^{[footnote 4]}, and a multi-media marketing campaign launched by UKHSA in February 2024 ^{[footnote 5]} .

Whilst initiatives undertaken during outbreak periods remain important, we are reminded that the key to achieving and maintaining measles control is to improve coverage of MMR vaccine in the routine childhood programme.

Two doses of MMR vaccine remain the best way to protect children from measles, mumps and rubella infection. They are also the best way to protect those who work with vulnerable individuals and therefore indirectly protect immunosuppressed individuals, children and pregnant women who are at greatest risk.

Our June 2024 issue reminded us of tried and tested ways to improve uptake, so please do re-visit this and links to the wealth of resources for download or order ^{[footnote 6]}.

Back-to-school resources

Flu vaccination briefing for primary schools

Available to order and download for free from the Health Publications website using product code: FLUPY24.

Additional information is available online.

Adolescent vaccination programme: briefing for secondary schools

Available to order and download for free from the Health Publications website using product code: FLUSY24. Additional information is available online.

Immunisation resources for teenagers and young people

• Immunisation of teenagers and young people – product code: 24YPG1EN
• a guide to the MenACWY vaccine – product code: YPMACWY1EN, also available in a range of community languages – a guide to the 3-in-1 teenage booster – product code: YP3BG1EN, also available in a range of community languages
• a guide to HPV vaccination for all – product code: HPVU1L, also available in a range of community languages

Save a life campaign

Resources for the ‘Save a Life’ MenACWY campaign are available to order and download and include:

• a campaign booklet
• A5 sticker
• social media cards
• animation video and banners
• posters for universities and further education settings
• banner artwork.

Know the signs and symptoms of meningitis and septicaemia

These resources describe the warning signs of meningitis, so that teenagers and young people, those entering a new college or university in particular, know what to look out for if someone falls ill.

It also reminds young people that they are eligible for the free MenACWY vaccine until age 25 to help protect them from some of the main causes of meningitis and septicaemia.

Printed copies of this poster and leaflet can be ordered for free from Health Publications.

Translations in 32 community languages are also available.

Starting a new school posters and postcards for all age groups

These posters and postcards are aimed at parents and carers to remind them to check that their child is up to date with their vaccinations. It features the measles, mumps and rubella (MMR) vaccine and the pre-school booster.

They are suitable for all GP practices, schools and nursery settings and are available free to order.

• nursery school poster. Product code: STARTNU1
• primary school poster. Product code: STARTPR1
• secondary school poster. Product code: STARTSE1
• nursery school postcard. Product code: STARTNU2
• primary school postcard. Product code: STARTPR2
• secondary school postcard. Product code: STARTSE2

Vaccine communications toolkit for universities and other higher education settings

A vaccines communications toolkit for universities and other higher education settings is available to download. This toolkit contains information and resources on vaccines including MenACWY and MMR and the diseases they protect against.

The selective neonatal hepatitis B immunisation pathway – importance of the 4-week dose and handover of care

Babies born to mothers who have screened positive for hepatitis B virus (HBV) in pregnancy, or whose mothers have acute hepatitis B infection in pregnancy, are offered an accelerated course of hepatitis B immunisation starting at birth and continuing as part of the routine childhood immunisation programme with hexavalent vaccine. High risk infants (born to women with HBV infection) should receive monovalent hepatitis B vaccine at birth and 4 weeks of age and then 3 doses of the hexavalent vaccine at 8, 12 and 16 weeks of age. They should receive a dose of monovalent hepatitis B vaccine at 12 months of age, at which time they should also have a blood test to check for infection.

Any missed or delayed doses may impact on the effectiveness of immunisation in preventing the infant from becoming infected with HBV. It is therefore important that regional teams, primary care, and child health records departments (CHRDs) have robust processes in place to ensure that babies are vaccinated at the right time, regardless of whether they have moved out of area, either permanently or temporarily.

The document Guidance on the hepatitis B antenatal screening and selective neonatal immunisation pathway has more information on the pathway, including sections on missed or delayed doses of vaccine and the importance of handover of care.

There are also links explaining how to register with a GP surgery outside your local area. Anyone in England can register with a GP practice and see a primary care doctor or nurse for free. You do not need to provide proof of identity, address or of immigration status to register with a GP practice. This also applies if you are an asylum seeker, refugee, a homeless patient, or an overseas visitor, whether lawfully in the UK or not. More information is available in the document Moved to the UK: migrant immunisation.

As the dose of hepatitis B vaccine due at 4 weeks of age is not part of the routine schedule, the infant may miss a dose if an appointment is not made for the infant to attend primary care specifically for this dose. Good communication and collaborative working are key to ensuring the 4-week vaccine dose is given on time.

Timely vaccination of the baby is critical, any delay will increase the chances of the baby developing chronic HBV infection.

UKHSA provides patient leaflets to support the programme, including Protecting your baby against hepatitis B and Hepatitis B: a guide to your care in pregnancy and after your baby is born.

Immunisation resources stand tour

The Immunisation Publications and Nursing team will be at a number of events in the next few months with the immunisation tour stand and we hope to see you. There will be an opportunity to collect resources and have a chat with about any vaccination or immunisation resource queries.

We will be at:

• Pulse Live in Newcastle on 5 September
• the Maternity and Midwifery Festival South West on 17 September
• the PCN Immunisation study day in London on 18 September

Don’t worry if none of these events are local to you, we will be attending many more across the country over the coming months and resources are always available to order to be delivered to you for free from Health Publications.

Vaccine supply: routine immunisation programme

August bank holiday deliveries warning notice

Due to the August bank holiday, there will be no deliveries or order processing by Movianto UK on Monday 26 August 2024. For all ImmForm customers with a standard delivery day of Monday, please be aware that after Monday 19 August, your next available delivery day will be Monday 2 September 2024.

For offshore COVID vaccine customers with a standard delivery day of Wednesday, please be aware that there will be no deliveries of COVID vaccine on Wednesday 28 August to Jersey, Guernsey, Isle of Man, or Scottish customers in Shetland, Orkney and Western Isles. Your next available delivery day will be Wednesday 4 September. You are reminded to be prepared for the break in deliveries and to order accordingly. Please make sure you have enough room in your fridge for any additional vaccine you wish to stock over this holiday period, bearing in mind the recommendation that only 2 to 4 weeks of vaccine stock be held at any one time.

August bank holiday orders and deliveries

Order cut off dates for the August bank holiday (Monday 26 August 2024)

Delivery date	Order cut-off date	Order cut-off time
Monday 19 August 2024	Thursday 15 August 2024	11.55am
Tuesday 20 August 2024	Friday 16 August 2024	11.55am
Wednesday 21 August 2024	Monday 19 August 2024	11.55am
Thursday 22 August 2024	Tuesday 20 August 2024	11.55am
Friday 23 August 2024	Wednesday 21 August 2024	11.55am
Monday 26 August 2024	Closed – No deliveries or order processing	-
Tuesday 27 August 2024	Thursday 22 August 2024	11.55am
Wednesday 28 August 2024 See above for offshore COVID customers	Friday 25 August 2024	11.55am
Thursday 29 August 2024	Tuesday 27 August 2024	11.55am
Friday 30 August 2024	Wednesday 28 August 2024	11.55am
Friday 1 September 2024	Thursday 29 August 2024	11.55am

Please be advised that emergency or ‘out of schedule’ deliveries cannot be arranged for failure to place orders in good time. Contact the ImmForm Team at:

• email: helpdesk@immform.org.uk
• telephone: 0844 376 0040

Change of vaccine brand for meningococcal groups

A, C, W and Y (MenACWY) vaccination from September 2024

From September 2024, the vaccine used for meningococcal groups A, C, W and Y (MenACWY) vaccination will change from Nimenrix® to MenQuadfi®. Please continue to order and administer Nimenrix® until ImmForm and local stock holdings deplete. MenQuadfi® vaccine will be made available to order via ImmForm during August 2024.

MenQuadfi® vaccine ordered via ImmForm will be supplied as a single dose pack, containing one vial of vaccine and a patient information leaflet (PIL). The pack does not contain a needle or a syringe for administration. Guidance on the choice of needle size can be found in the Green Book Chapter 4. Needles and syringes should be obtained locally.

MenQuadfi® and Nimenrix® vaccines and are packed in different sized cartons. Please ensure you have enough fridge capacity before placing any orders. To help with planning storage requirements, the dimensions are:

• MenQuadfi® is 58 x 32 x 45mm (H x W x D)
• Nimenrix® was 57 x 27 x 135mm (H x W x D)

Please add MenQuadfi® to your routine ImmForm order where possible, rather than creating additional orders. To minimise wastage due to fridge failures, please order no more than 2 weeks’ worth of stock.

High-level ordering controls will be in place to reduce the risk of ordering errors only. These are not intended to restrict activity. Any further updates to ordering information will be published online as an ImmForm news article.

Details about the meningococcal vaccination programme are published in the Green Book Chapter 22 Further details about MenQuadfi® vaccine can be found in the MenQuadfi solution for injection summary of product characteristics (SmPC).

Contact the helpdesk@immform.org.uk for ordering queries.

Change of vaccine for the pertussis (whooping cough)

vaccination in pregnancy programme from 1 July 2024

From 1 July 2024, the vaccine used for the pertussis (whooping cough) vaccination in pregnancy programme has changed from Boostrix-IPV® to ADACEL®. Please refer to this publication for full details see the letter about Prenatal pertussis vaccine change from July 2024.

ADACEL® is now available to order via ImmForm. Boostrix-IPV® will continue to be the vaccine used for the pre-school booster vaccination of children, and for the maternal programme if ADACEL® is not available or is otherwise unsuitable (such as in individuals with a severe allergy to latex).

Providers who do not administer pre-school boosters and were unable to use up locally held stock of Boostrix-IPV® ahead of the change on 1 July 2024, may offer any remaining locally held stock of Boostrix-IPV® to pregnant women if this will prevent vaccine wastage.

ADACEL® vaccine ordered via ImmForm is supplied as a single dose pack, containing one pre-filled syringe. The pack does not contain a needle for administration. Guidance on the choice of needle size can be found in the Green Book Chapter 4. Needles should be obtained locally. Please add ADACEL® to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, please order no more than 2 weeks’ worth of stock.

High-level ordering controls will be in place to reduce the risk of ordering errors only. These are not intended to restrict activity. Any further updates to ordering information will be published online as an ImmForm news article.

Details about the pertussis (whooping cough) vaccination programme is published in the Green Book, Pertussis: the green book, chapter 24.

Further details about ADACEL® vaccine can be found in the ADACEL suspension for injection in pre-filled syringe summary of product characteristics (SmPC).

Contact the helpdesk@immform.org.uk for ordering queries.

Introduction of Abrysvo® RSV vaccine for older adults and during pregnancy for infant protection

From 1 September 2024, RSV (respiratory syncytial virus) programmes will be introduced for older adults and during pregnancy for infant protection, see introduction of new NHS vaccination programmes against respiratory syncytial virus (RSV) for full detals.

The same RSV vaccine, Abrysvo®, will be used for both programmes.

Abrysvo® vaccine is now available to customers in England and Wales to order via ImmForm.

Scottish customers should refer to local ordering guidance. Abrysvo® vaccine ordered via ImmForm will be supplied as a single dose pack, containing one vial of vaccine, diluent for reconstitution and patient information leaflet (PIL).

Each pack will also contain one 25 G x 25mm (1 inch) needle. Guidance on the choice of needle size can be found in the Green Book Chapter 4. If required, other sizes of needles should be obtained locally.

The pack of Abrysvo® vaccine is physically larger than most other vaccines supplied via ImmForm. Please ensure you have enough fridge capacity before placing any orders. To help with planning storage requirements, each single dose pack measures 73mm x 35mm x 116mm (H x W x D).

When ordering Abrysvo® vaccine, orders should be placed for the ImmForm product that is specific to each RSV protection programme. Product ordered for the infant RSV protection programme (offered to pregnant women) should not be used for the older adult RSV protection programme and vice versa. Account holders will see 2 different product lines and should order accordingly.

Packs	Brand	Total items or doses	Total pack price
1	Abrysvo maternal vaccine for infant protection	1	£158.00
1	Abrysvo vaccine for adult protection	1	£158.00

High-level ordering controls will be in place to reduce the risk of ordering errors only. These are not intended to restrict activity. Any further updates to ordering information will be published online as an ImmForm news article. To minimise wastage due to fridge failures, please order no more than 2 weeks’ worth of stock. Details about the RSV vaccination programmes can be found in Green Book Chapter 27a.

Further details about Abrysvo® vaccine can be found at the Abrysvo powder and solvent for solution for injection summary of product characteristics (SmPC).

Contact the helpdesk@immform.org.uk for ordering queries.

Vaccines for the 2024 to 25 children’s flu programme supplied by UKHSA

From 2024 LAIV will be a trivalent vaccine (rather than a quadrivalent) due to the removal of the B-Yamagata strain. This change in formulation by AstraZeneca was recommended by the World Health Organisation and is supported by the Joint Committee on Vaccination and Immunisation. The brand name for the trivalent vaccine is Fluenz® (the quadrivalent vaccine was named Fluenz® Tetra).

Presentation of the vaccine (that is, pre-filled single dose nasal spray, supplied in a ten dose pack) remains the same, and LAIV will be available to order via ImmForm for providers of the children’s flu programme as usual.

All flu vaccines for the 2024 to 2025 children’s flu programme will be available to order by NHS providers in England via ImmForm.

UKHSA does not supply any flu vaccines for patients aged 18 years and over.

Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Vaccines and availability

The 2 vaccines that will be available, preliminary indicative ordering dates and the groups that these vaccines should be ordered for are set out in the table below. At present these timings remain subject to change. The latest and most accurate information on availability of centrally supplied vaccines for the children’s flu programme is available on the ImmForm news page at all times. It is strongly advised that all parties involved in the provision of influenza vaccines to children ensure they remain up to date with this.

The 2 vaccines available and the groups these vaccines should be ordered for are shown in the table below. The latest and most accurate information on availability of centrally supplied vaccines for the children’s flu programme is available on the ImmForm news page at all times. It is strongly advised that all parties involved in the provision of influenza vaccines to children ensure they remain up to date with this.

Vaccine	Manufacturer	Available to order for	Anticipated order opening for providers
Fluenz® (LAIV)	AstraZeneca	- all children from 2 years of age to school year 11 - children in clinical risk groups aged 2 to <18 years [footnote 7]	Early-mid September
Cell-based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc)	Seqirus	- children in clinical risk groups aged 6 months to <2 years - all other eligible [footnote 8] children aged 2 to <18 years for whom LAIV is unsuitable	Early September

Editing Fluenz® (LAIV) orders

Due to the anticipated large volume of orders for Fluenz® in the first few weeks of ordering, orders for this product will be assembled as soon as they are placed and will not be editable. If you need to make an adjustment to your order after it has been placed, you will need to contact the helpdesk@immform.org.uk for ordering queries.

LAIV ordering information for general practice

Ordering controls will be in place for general practices, to enable UKHSA to balance supply with demand. These controls will work by allocating an amount of LAIV based on the number of registered eligible patients and will be tailored to each practice.

UKHSA expects to be able to accommodate the following but please note, this information remains subject to change:

• each GP practice will initially be allocated sufficient LAIV to vaccinate at least 45% of their eligible patients (all 2 and 3 year olds, plus children in clinical risk groups from age 4 to <18 years) when ordering commences
• increases to these allocations will be made in response to demand and vaccine availability
• requests for extra vaccine will be considered on a case-by-case basis throughout the ordering period. Requests for additional vaccine should be sent to helpdesk@immform.org.uk and should be sent in good time before your order cut-off – out-of-schedule deliveries will be by exception only

Multi-branch practices and LAIV allocations

Please note that GP practices or groups that operate over multiple sites but are part of the same organisation will have a joint allocation (as in previous years), even where each site has a unique ImmForm account. This means that it is possible for one site to potentially order all of the available vaccine for the group, unless there is local agreement on how the allocated volume is shared. UKHSA recommend that this agreement is in place before ordering opens to reduce the risk of supply interruption. The information above allows practices to estimate the amount of vaccine they will be initially allocated, and how it should be split between all sites.

LAIV ordering information for school-age providers

A default weekly ordering cap of 450 packs (4,500 doses) per week will be in place for school provider accounts.

Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example, where a provider covers a large area using a single account), a higher weekly cap should be requested via the UKHSA Flu Vaccine Operations team by emailing childfluvaccine@ukhsa.gov.uk. Requests should be made by Friday 30 August to ensure that accounts are set up correctly before vaccine ordering commences.

For one-off larger orders during the ordering period, requests should be made via helpdesk@immform.org.uk

Inactivated flu vaccine ordering

The Cell Based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc) will be available to order, in a single dose pack, for:

• children in clinical risk groups aged from 6 months to less than 2 years old
• children aged from 2 to <18 years old in clinical risk groups for whom LAIV is clinically contraindicated or otherwise unsuitable
• healthy children from 2 years old to those in school year 11, for whom LAIV is unsuitable (for example, due to objection to LAIV on the grounds of its porcine gelatine content)

Order controls will also be in place for this vaccine as follows:

• for GPs, there will be an initial cap of 10 doses/packs per week
• for school-age providers, there will be a cap of 450 doses/packs per week

All influenza vaccines for the 2024 to 2025 season

Information on all influenza vaccines that have been marketed in the UK for the 2024 to 2025 flu season has been published.

The impact of changes to opening hours on routine vaccine deliveries

Please consider temporary changes to opening times when placing ImmForm orders. If you are aware of a scheduled site closure, please refrain from placing an order for that date. In case of a one-off closure, consider rescheduling your order for the week before or after. This approach will contribute to improved overall efficiencies and enhance delivery performance for the benefit of all customers.

It is not possible to accommodate one-off changes to delivery days. Customers should report long-term changes to the days and times when they can accept deliveries, such as routine training days and closures, by contacting Movianto UK Customer Care at MoviantoUK.NHSCC@movianto.com or telephone 01234 587207. This should not be used to report short-term changes due to absence or holidays.

DTaP/IPV/Hib/HepB vaccine ordering

Supplies of DTaP/IPV/Hib/HepB vaccines Infanrix hexa® and Vaxelis® are available for the routine infant primary immunisations programme.

Orders for Infanrix hexa® remain unrestricted. Customers in England and Wales may order up to 20 packs of Vaxelis® per ImmForm account per week. Customers in Scotland should refer to their local ordering restrictions. Providers should not order more than 2 weeks’ worth of stock to minimise wastage due to fridge failures. For assistance, please contact the ImmForm Helpdesk at helpdesk@immform.org.uk

The EU Falsified Medicines Directive and Delegated Regulation as applicable to UKHSA-supplied vaccines for the national immunisation programme

The EU Falsified Medicines Directive (FMD) and Delegated Regulation impose legal obligations on the EU medicines supply chain to prevent entry of falsified medicinal products into the supply chain. The Delegated Regulation was implemented in all EU member states on 9 February 2019. Following the UK’s departure from the EU, the Delegated Regulation ceased to apply in Great Britain from 31 December 2020, but continues to apply in Northern Ireland.

Information for customers in Northern Ireland

FMD-barcoded packs of routine immunisation programme vaccines that are centrally supplied by UKHSA continue to be supplied with active FMD serialisation, and should be decommissioned by end users in Northern Ireland. Customers in Northern Ireland who access centrally supplied vaccines are encouraged to review local guidance on implementation of the EU FMD.

MMR vaccine ordering

In order to rebalance central supplies of both measles, mumps, and rubella (MMR vaccines), please consider ordering M-M-RvaxPRO® as your first choice, which is available to all customers without restriction.

Customers in England and Wales who require Priorix®, for example because you serve communities that do not accept vaccines containing porcine gelatine, may order up to 15 packs of Priorix® per ImmForm account per week. For assistance with ordering more than 15 packs of Priorix®, please email your request to the ImmForm Helpdesk at helpdesk@immform.org.uk.

Customers in Scotland should refer to their local ordering restrictions.

Non-routine vaccine supply

Hepatitis A vaccine

Adult:

• GSK: supply of Havrix Adult PFS singles and packs of 10 are currently available
• Sanofi: Avaxim PFS singles are currently available. Avaxim packs of 10 are unavailable
• MSD: VAQTA Adult is available

Paediatric:

• GSK: supply of Havrix Paediatric singles and packs of 10 are currently available
• MSD: VAQTA Paediatric is available
• Sanofi: Avaxim Junior singles are currently available

Hepatitis B vaccine

Adult:

• GSK: Engerix B PFS singles and packs of 10 are currently available
• GSK: supply of Fendrix is currently available
• MSD: HBVAXPRO 10 micrograms is available
• MSD: HBVAXPRO 40 micrograms is available
• Valneva: PreHevbri is available

Paediatric:

• GSK: supply of Engerix B Paediatric singles is currently available
• MSD: HBVAXPRO 5 micrograms is available

Combined hepatitis A and B vaccine

• GSK: Twinrix Adult singles and packs of 10 are available
• GSK: Twinrix Paediatric is currently available
• GSK: Ambirix is available

Combined hepatitis A and Typhoid vaccine

Sanofi: Viatim is now a discontinued product and no longer available for sale.

Typhoid vaccine

• Sanofi: Typhim singles and packs of 10 are available
• Patientric: Vivotif is available

Rabies vaccine

• Valneva; Rabipur is currently unavailable
• Sanofi: Verorab currently out of stock

Pneumococcal polysaccharide vaccine (PPV)

MSD: supply of Pneumovax 23 (PPV23) PFS is available.

Pneumococcal polysaccharide conjugate vaccine (PCV)

• Pfizer: Prevenar 13 is currently available
• MSD: Vaxneuvance is currently available

Varicella zoster vaccine

• GSK: VARILRIX is currently available
• MSD: VARIVAX is available
• MSD: ZOSTAVAX is now a discontinued product

Diphtheria, tetanus, poliomyelitis (inactivated) vaccine

Sanofi: Revaxis is available.

Diphtheria, tetanus, pertussis (acellular) and (inactivated) vaccine

• GSK: supply of Boostrix-IPV is currently available
• Sanofi: Repevax is currently available

MMR

• MSD: MMR Vaxpro is currently available
• GSK: Priorix is currently available

Meningitis ACWY vaccine

• GSK: Menveo is currently available
• Pfizer: Nimenrix is currently available
• Sanofi: MenQuadfi is available

Yellow fever

Sanofi : Stamaril is available.

Human papillomavirus (HPV) vaccine

• MSD: GARDASIL has been discontinued
• MSD: Gardasil 9 is currently available
• GSK: Cervarix has been discontinued

Cholera vaccine

• Valneva: Dukoral is available
• Patientric: Vaxchora is available

Japanese encephalitis vaccine

Valneva: Ixiaro is available.

Meningococcal group B vaccine

GSK: Bexsero is currently available.

Diphtheria, tetanus, pertussis, hib vaccine and poliomyelitis

GSK: Infanrix IPV+Hib is currently available.

Hib + meningococcal group c combined vaccine

GSK: Menitorix is currently available.

Live attenuated rotavirus vaccine

GSK: Rotarix is currently available.

Herpes zoster vaccine

GSK: Shingrix is currently available.

Diphtheria, tetanus and pertussis

Sanofi: ADACEL is available to order without restrictions.

Dengue tetravalent vaccine

Takeda: Qdenga is currently available.

1. UKHSA data dashboard ↩

2. EDCE communicable threats report ↩

3. Vaccine update: issue 341, August 2023 ↩

4. NHS England – Confirmation of national vaccination and immunisation catch-up campaign for 2023 to 2024 season ↩

5. UKHSA marketing campaign launches to drive up childhood vaccinations ↩

6. Vaccine update: issue 346, June 2024 ↩

7. Unless LAIV clinically contraindicated or otherwise unsuitable.  ↩

8. Children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to <18 years.  ↩